SciSparc Ltd. (SPRC)Healthcare | Biotechnology | Tel Aviv-Yafo, Israel | NasdaqCM
6.58 USD
-0.04
(-0.604%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 6.51 -0.07 (-0.070%) ⇩ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 5:55 a.m. EDT
The immediate outlook is severely clouded by a catastrophic multi-year price collapse. Over the last four years, the stock has lost nearly 99.8% of its value, with every single year showing a double-digit decline. This relentless downward trajectory suggests the market has permanently reassessed the business quality, rendering any short-term technical bounce highly suspect. Fundamentally, the company is in distress: revenue has contracted by roughly 35%, profitability is nonexistent with negative operating margins, and return on equity is deeply negative. While the recent news headlines regarding a Phase IIb trial for a Tourette's drug offer a potential catalyst for a speculative rebound, the underlying financial engine is broken, and the balance sheet shows significant operational cash burn despite some free cash flow. There is no dividend to provide a floor, and the lack of analyst coverage leaves the stock vulnerable to further volatility. Investors should view this as a high-risk speculative play rather than an investment, given the overwhelming evidence of structural deterioration. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.410767 |
| AutoARIMA | 0.414501 |
| MSTL | 0.470313 |
| AutoTheta | 0.764134 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 26% |
| H-stat | 3.97 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.199 |
| Excess Kurtosis | -0.80 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 7.111 |
| Revenue per Share | 6.893 |
| Market Cap | 151,821,936 |
| Trailing P/E | 0.07 |
| Beta | 2.45 |
| Previous Name | Therapix Biosciences Ltd. |
| Website | https://scisparc.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.69854283 |
| Address1 | Tower A |
| Address2 | 2nd Floor 20 Raul Wallenberg Street |
| All Time High | 41,769.0 |
| All Time Low | 0.0 |
| Ask | 8.35 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 40,110 |
| Average Daily Volume3 Month | 343,467 |
| Average Volume | 343,467 |
| Average Volume10Days | 40,110 |
| Beta | 2.449 |
| Bid | 4.79 |
| Bid Size | 2 |
| Book Value | 11.6 |
| City | Tel Aviv-Yafo |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.58 |
| Current Ratio | 2.413 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 6.75 |
| Day Low | 6.5 |
| Debt To Equity | 7.111 |
| Display Name | SciSparc |
| Earnings Timestamp End | 1,745,524,800 |
| Earnings Timestamp Start | 1,745,524,800 |
| Ebitda | -8,528,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.053 |
| Enterprise To Revenue | 0.531 |
| Enterprise Value | 454,938 |
| Eps Trailing Twelve Months | 97.04 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 6.1179 |
| Fifty Day Average Change | 0.46210003 |
| Fifty Day Average Change Percent | 0.07553246 |
| Fifty Two Week Change Percent | -69.85429 |
| Fifty Two Week High | 80.1 |
| Fifty Two Week High Change | -73.52 |
| Fifty Two Week High Change Percent | -0.91785264 |
| Fifty Two Week Low | 2.98 |
| Fifty Two Week Low Change | 3.6 |
| Fifty Two Week Low Change Percent | 1.2080537 |
| Fifty Two Week Range | 2.98 - 80.1 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,630,330,200,000 |
| Float Shares | 553,655 |
| Free Cashflow | 833,000 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 3 |
| Fullday Change | -0.04 |
| Fullday Change Percent | -0.604229 |
| Fullday Price | 6.51 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.73714995 |
| Gross Profits | 631,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.0938 |
| Implied Shares Outstanding | 23,073,243 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-12-22 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,772,582,400 |
| Last Split Factor | 1:9 |
| Long Business Summary | SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and palmitoylethanolamide oral tablets CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel. |
| Long Name | SciSparc Ltd. |
| Market | us_market |
| Market Cap | 151,821,936 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_23813054 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-08-28 |
| Net Income To Common | -12,179,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 3,863,470 |
| Open | 6.75 |
| Operating Cashflow | -4,137,000 |
| Operating Margins | -8.48949 |
| Payout Ratio | 0.0 |
| Phone | 972 7 334 47180 |
| Post Market Change | -0.069999695 |
| Post Market Change Percent | -1.0638251 |
| Post Market Price | 6.51 |
| Post Market Time | 1,787,959,806 |
| Prev Name | Therapix Biosciences Ltd. |
| Previous Close | 6.62 |
| Price Hint | 2 |
| Price To Book | 0.5672414 |
| Price To Sales Trailing12 Months | 177.36208 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.131 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.03999996 |
| Regular Market Change Percent | -0.60422903 |
| Regular Market Day High | 6.75 |
| Regular Market Day Low | 6.5 |
| Regular Market Day Range | 6.5 - 6.75 |
| Regular Market Open | 6.75 |
| Regular Market Previous Close | 6.62 |
| Regular Market Price | 6.58 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 84,130 |
| Return On Assets | -0.60681 |
| Return On Equity | -1.7839 |
| Revenue Growth | -0.345 |
| Revenue Per Share | 6.893 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 23,073,243 |
| Shares Percent Shares Out | 0.03 |
| Shares Short | 17,206 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 10,052 |
| Short Name | SciSparc Ltd. |
| Short Percent Of Float | 0.03 |
| Short Ratio | 0.04 |
| Source Interval | 15 |
| Symbol | SPRC |
| Total Cash | 4,591,000 |
| Total Cash Per Share | 8.009 |
| Total Debt | 366,000 |
| Total Revenue | 856,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 97.04 |
| Trailing P E | 0.067807086 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.479655 |
| Two Hundred Day Average Change | -1.8996553 |
| Two Hundred Day Average Change Percent | -0.22402507 |
| Type Disp | Equity |
| Volume | 84,130 |
| Website | https://scisparc.com |
| Zip | 6,971,916 |